Theravance Biopharma Liabilities 2024

Theravance Biopharma Aktienanalyse

What does Theravance Biopharma do?

Theravance Biopharma Inc is a company that was founded in 2014 and is headquartered in South San Francisco, California. The company is a spin-off of Theravance Inc, which was founded in 1996 and specialized in the development of drugs for respiratory diseases and infections. The business model of Theravance Biopharma is to develop and market innovative drugs for severe respiratory diseases, infections, and immunological disorders. The company works closely with its partners and scientific network to discover, develop, and market new drugs. Theravance Biopharma is divided into several business units, including Theravance Biopharma R&D, which focuses on drug discovery and development, and Theravance Biopharma Commercialization, which focuses on marketing Theravance's products. The company has developed and launched a number of products, including the branded products Vibativ and Velusetrag. Vibativ is an antibiotic used to treat severe lung infections and other infections, while Velusetrag was developed for the treatment of chronic constipation in patients with gastrointestinal disorders such as irritable bowel syndrome. The company also has a broad pipeline of products in various stages of development. This includes drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD), autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis, as well as infections such as MRSA and pneumococcal. Theravance Biopharma has also formed a strong partnership with GSK (GlaxoSmithKline), one of the world's leading pharmaceutical companies. The two companies are working together to develop drugs to help patients with severe respiratory diseases, infections, and immune disorders. In summary, Theravance Biopharma is an innovative company that focuses on the discovery, development, and commercialization of drugs for the treatment of severe respiratory diseases, infections, and immune disorders. The company has a strong pipeline of products in various stages of development and a strong partnership with GSK to continue providing innovative solutions for patients with severe illnesses. Theravance Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Theravance Biopharma's Liabilities

Theravance Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Theravance Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Theravance Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Theravance Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Theravance Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Theravance Biopharma stock

What is the level of liabilities of Theravance Biopharma this year?

Theravance Biopharma has a debt balance of 169 M USD this year.

What were the liabilities of Theravance Biopharma compared to the previous year?

The liabilities of Theravance Biopharma have increased by 2.06% increased compared to the previous year.

What are the consequences of high debt for investors of Theravance Biopharma?

High liabilities can pose a risk for investors of Theravance Biopharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Theravance Biopharma?

Low liabilities mean that Theravance Biopharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Theravance Biopharma affect the company?

An increase in liabilities of Theravance Biopharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Theravance Biopharma affect the company?

A decrease in the liabilities of Theravance Biopharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Theravance Biopharma?

Some factors that can influence the liabilities of Theravance Biopharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Theravance Biopharma so important for investors?

The liabilities of Theravance Biopharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Theravance Biopharma take to modify the liabilities?

To change its liabilities, Theravance Biopharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Theravance Biopharma pay?

Over the past 12 months, Theravance Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theravance Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Theravance Biopharma?

The current dividend yield of Theravance Biopharma is .

When does Theravance Biopharma pay dividends?

Theravance Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theravance Biopharma?

Theravance Biopharma paid dividends every year for the past 0 years.

What is the dividend of Theravance Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theravance Biopharma located?

Theravance Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theravance Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theravance Biopharma from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Theravance Biopharma pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Theravance Biopharma in the year 2023?

In the year 2023, Theravance Biopharma distributed 0 USD as dividends.

In which currency does Theravance Biopharma pay out the dividend?

The dividends of Theravance Biopharma are distributed in USD.